1. Galiè, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
Google Scholar | Crossref | Medline | ISI2. Hoeper, MM, Humbert, M, Souza, R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306–322.
Google Scholar | Crossref | Medline3. Lau, EMT, Giannoulatou, E, Celermajer, DS, et al. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017; 14: 603–614.
Google Scholar | Crossref | Medline4. Stacher, E, Graham, BB, Hunt, JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261–272.
Google Scholar | Crossref | Medline | ISI5. NHS UK. National PH Audit. 2019 [2/10/2020]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/national-pulmonary-hypertension-audit/2019.
Google Scholar6. Schermuly, RT, Ghofrani, HA, Wilkins, MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011; 8: 443–455.
Google Scholar | Crossref | Medline | ISI7. Schermuly, RT, Dony, E, Ghofrani, HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811–2821.
Google Scholar | Crossref | Medline | ISI8. Ghofrani, HA, Seeger, W, Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412–1413.
Google Scholar | Crossref | Medline | ISI9. Ghofrani, HA, Morrell, NW, Hoeper, MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171–1177.
Google Scholar | Crossref | Medline | ISI10. Hoeper, MM, Barst, RJ, Bourge, RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128–1138.
Google Scholar | Crossref | Medline | ISI11. Capdeville, R, Buchdunger, E, Zimmermann, J, et al. Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493–502.
Google Scholar | Crossref | Medline | ISI12. Perros, F, Montani, D, Dorfmüller, P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81–88.
Google Scholar | Crossref | Medline | ISI13. Montani, D, Perros, F, Gambaryan, N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 184: 116–123.
Google Scholar | Crossref | Medline | ISI14. Yu, Y, Sweeney, M, Zhang, S, et al. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 2003; 284: C316–C330.
Google Scholar | Crossref | Medline | ISI15. Abe, K, Toba, M, Alzoubi, A, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 2011; 45: 804–808.
Google Scholar | Crossref | Medline | ISI16. Rieg, AD, Bünting, NA, Cranen, C, et al. Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices. Respir Res 2019; : 111.
Google Scholar | Crossref | Medline17. Patterson, KC, Weissmann, A, Ahmadi, T. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152–153.
Google Scholar | Crossref | Medline | ISI18. Souza, R, Sitbon, O, Parent, F, et al. Long term Imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
Google Scholar | Crossref | Medline | ISI19. Olschewski, H. Imatinib for pulmonary arterial hypertension - wonder drug or killer drug? Respiration 2015; 89: 513–514.
Google Scholar | Crossref | Medline20. ClinicalTrials.gov Identifier : NCT04903730, https://clinicaltrials.gov/ct2/show/NCT04903730?term = imatinib+inhaled&cond = Pulmonary+Hypertension&draw = 2&rank = 1 (accessed August 2021).
Google Scholar21. Hochhaus, A, Larson, RA, Guilhot, F, et al. Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376: 917–27.
Google Scholar | Crossref | Medline | ISI22. Reichardt, P. The story of Imatinib in GIST – a journey through the development of a targeted therapy. Oncol Res Treat 2018; 41: 472–477.
Google Scholar | Crossref | Medline23. Renard, D, Bouillon, T, Zhou, P, et al. Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. Br J Clin Pharmacol 2015; 80: 75–85.
Google Scholar | Crossref | Medline24. Cheah, CY, Burbury, K, Apperley, JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with Imatinib. Blood 2014; 123: 3574–3577.
Google Scholar | Crossref | Medline25. Jawhar, M, Naumann, N, Schwaab, J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol 2017; 96: 1463–1470.
Google Scholar | Crossref | Medline26. Suhre, K, Arnold, M, Bhagwat, AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun 2017; 8: 14357.
Google Scholar | Crossref | Medline27. Sun, BB, Maranville, JC, Peters, JE, et al. Genomic atlas of the human plasma proteome. Nature 2018; 558: 73–79.
Google Scholar | Crossref | Medline28. Gudjonsson, A, Gudmundsdottir, V, Axelsson, GT, et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. bioRxiv 2021.07.02.450858.
Google Scholar29. O’Quigley, J, Pepe, M, Fisher, L. Continual reassessment method: a practical design for phase I clinical studies in cancer. Biometrics 1990; 46: 33–48.
Google Scholar | Crossref | Medline | ISI30. Simon, Richard. Optimal two-stage designs for phase II clinical trials. Control Clin Trial 1989; 10: 1–10.
Google Scholar | Crossref | Medline31. Ventetuolo, CE, Gabler, NB, Fritz, JS, et al. Are hemodynamics surrogate end points in pulmonary arterial hypertension? Circulation 2014; 130: 768–775.
Google Scholar | Crossref | Medline | ISI32. Weatherald, J, Boucly, A, Chemla, D, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation 2018; 137: 693–704.
Google Scholar | Crossref | Medline33. Law, Martin, Grayling MJ and Mander AP. Optimal curtailed designs for single arm phase II clinical trials. arXiv preprint arXiv:1909.03017 (2019).
Google Scholar34. Law, M, Grayling, MJ, Mander, AP. A stochastically curtailed two-arm randomised phase II trial design for binary outcomes. Pharmaceutical Statistics 2021; 20: 212–228.
Google Scholar | Crossref | Medline35. Frost, AE, Barst, RJ, Hoeper, MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 2015; 34: 1366–1375.
Google Scholar | Crossref | Medline | ISI36. Schmidli, H, Peng, B, Riviere, GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005; 60: 35–44.
Google Scholar | Crossref | Medline37. Medarametla, V, Festin, S, Sugarragchaa, C, et al. PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension. Pulm Circ 2014; 4: 82–102.
Google Scholar | SAGE Journals | ISI